Birchview Capital’s Immunogen Inc IMGN Stock Holding History

Birchview Capital’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-188,000	Closed	-$5.57M	–	60
2023 Q4	$5.57M	Sell	188,000 -2,000	-1%	-$39.8K	4.36%	6
2023 Q3	$3.02M	Hold	190,000	–	–	2.56%	8
2023 Q2	$3.59M	Buy	190,000 +40,000	+27%	+$472K	2.69%	8
2023 Q1	$576K	Hold	150,000	–	–	0.45%	31
2022 Q4	$744K	Hold	150,000	–	–	0.53%	26
2022 Q3	$717K	Hold	150,000	–	–	0.5%	33
2022 Q2	$675K	Sell	150,000 -40,000	-21%	-$174K	0.49%	31
2022 Q1	$904K	Hold	190,000	–	–	0.65%	29
2021 Q4	$1.41M	Hold	190,000	–	–	0.91%	20
2021 Q3	$1.08M	Hold	190,000	–	–	0.73%	27
2021 Q2	$1.25M	Hold	190,000	–	–	0.75%	22
2021 Q1	$1.54M	Hold	190,000	–	–	0.91%	18
2020 Q4	$1.23M	Hold	190,000	–	–	0.71%	26
2020 Q3	$684K	Hold	190,000	–	–	0.46%	27
2020 Q2	$874K	Hold	190,000	–	–	0.53%	27
2020 Q1	$648K	Buy	190,000 +10,000	+6%	+$43.7K	0.57%	23
2019 Q4	$919K	Hold	180,000	–	–	0.67%	25
2019 Q3	$436K	Hold	180,000	–	–	0.29%	31
2019 Q2	$391K	Buy	180,000 +90,000	+100%	+$213K	0.24%	37
2019 Q1	$244K	Buy	90,000 +68,000	+309%	+$295K	0.15%	44
2018 Q4	$106K	Buy	+22,000	New	+$133K	0.1%	47

Other funds holding IMGN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Birchview Capital's IMGN Position: Q1 2024 in Review

Birchview Capital sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 188,000 shares — an estimated $5.57M sold.

Birchview Capital first reported a position in IMGN in Q4 2018 and held it in 21 quarters. The position peaked at $5.57M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

Birchview Capital reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
Birchview Capital sold 188,000 Immunogen Inc shares in Q1 2024, an estimated $5.57M.
Birchview Capital first reported a position in Immunogen Inc in Q4 2018 and held it in 21 quarters.
Birchview Capital's Immunogen Inc position peaked at $5.57M in Q4 2023.
3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Birchview Capital's 13F filing for Q1 2024, filed 14 May 2024.